Fluvoxamine, melatonin and COVID-19
- PMID: 33392622
- PMCID: PMC7779245
- DOI: 10.1007/s00213-020-05753-z
Fluvoxamine, melatonin and COVID-19
Comment on
-
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760. JAMA. 2020. PMID: 33180097 Free PMC article. Clinical Trial.
References
-
- Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, Miller JP, Yang L, Yingling M, Avidan MS, Reiersen AM. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292–2300. doi: 10.1001/jama.2020.22760. - DOI - PMC - PubMed
-
- von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol. 2000;56(2):123–127. doi: 10.1007/s002280050729. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical